A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
14
Participants
Timeline
Start Date
March 28, 2021
Primary Completion Date
August 4, 2021
Study Completion Date
September 3, 2021
Conditions
Amyloidosis
Interventions
DRUG
acoramidis
acoramidis
Trial Locations (1)
NG11 6JS
Quotient Sciences, Ruddington
All Listed Sponsors
lead
Eidos Therapeutics, a BridgeBio company
INDUSTRY
NCT04769479 - A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects | Biotech Hunter | Biotech Hunter